Crohn’s Disease – Epidemiology – Epidemiology – Crohn’s Disease – Mature Markets

Clarivate Epidemiology’s coverage of Crohn’s disease (CD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of CD for each country as well as annualized case counts projected to the national population.

Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are forecast across the major mature pharmaceutical markets.

Clarivate Epidemiology’s CD forecast will answer the following questions:

• Of all people diagnosed with CD, how many in each country in the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CD over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 16 CD patient populations, as follows:

• Diagnosed prevalent cases.
• Diagnosed incident cases.
• Diagnosed drug-treated (acute setting) prevalent cases.
• Diagnosed non-drug-treated (acute setting) prevalent cases.
• Diagnosed drug-treated (maintenance setting) prevalent cases.
• Diagnosed non-drug-treated (maintenance setting) prevalent cases.
• Diagnosed B1 (nonstricturing, nonfistulizing) prevalent cases.
• Diagnosed B2 (stricturing) prevalent cases.
• Diagnosed B3 (penetrating) prevalent cases.
• Diagnosed L1 (terminal ileum) prevalent cases.
• Diagnosed L2 (colonic) prevalent cases.
• Diagnosed L3 (ileocolonic) prevalent cases.
• Diagnosed prevalent cases in remission.
• Diagnosed mild CD prevalent cases.
• Diagnosed moderate CD prevalent cases.
• Diagnosed severe CD prevalent cases.

Note: Coverage may vary by country.